These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 11678934

  • 1. Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates.
    Gönüllü N, Aktaş Z, Salcioglu M, Bal C, Ang O.
    Clin Microbiol Infect; 2001 Sep; 7(9):499-503. PubMed ID: 11678934
    [Abstract] [Full Text] [Related]

  • 2. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Diagn Microbiol Infect Dis; 2001 Sep; 40(1-2):51-7. PubMed ID: 11448564
    [Abstract] [Full Text] [Related]

  • 3. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
    Lopez H, Stepanik D, Vilches V, Scarano S, Sarachian B, Mikaelian G, Finlay J, Sucari A.
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):187-92. PubMed ID: 11576792
    [Abstract] [Full Text] [Related]

  • 5. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
    McCloskey L, Moore T, Niconovich N, Donald B, Broskey J, Jakielaszek C, Rittenhouse S, Coleman K.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
    [Abstract] [Full Text] [Related]

  • 7. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.
    Blondeau JM, Hansen G, Metzler KL, Borsos S, Irvine LB, Blanco L.
    Int J Antimicrob Agents; 2003 Aug; 22(2):147-54. PubMed ID: 12927955
    [Abstract] [Full Text] [Related]

  • 8. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
    Aktaş Z, Gönüllü N, Salcioğlu M, Bal C, Anğ O.
    Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
    [Abstract] [Full Text] [Related]

  • 9. Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.
    García-Garrote F, Cercenado E, Martín-Pedroviejo J, Cuevas O, Bouza E.
    J Antimicrob Chemother; 2001 May; 47(5):681-4. PubMed ID: 11328784
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
    Yong DE, Cheong HJ, Kim YS, Park YJ, Kim WJ, Woo JH, Lee KW, Kang MW, Choo YS.
    J Korean Med Sci; 2002 Dec; 17(6):737-42. PubMed ID: 12482994
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.
    Koeth LM, Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Appelbaum PC.
    Int J Antimicrob Agents; 2002 Jan; 19(1):33-7. PubMed ID: 11814765
    [Abstract] [Full Text] [Related]

  • 12. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
    Felmingham D, Robbins MJ, Ingley K, Mathias I, Bhogal H, Leakey A, Ridgway GL, Grüneberg RN.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():43-9. PubMed ID: 9222069
    [Abstract] [Full Text] [Related]

  • 13. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
    Yamaguchi K, Miyazaki S, Kashitani F, Iwata M, Kanda M, Tsujio Y, Okada J, Tazawa Y, Watanabe N, Uehara N, Igari J, Oguri T, Kaimori M, Kawamura C, Iinuma Y, Nisawataira T, Tashiro H, Ueno K, Ishigo S, Yasujima M, Kawahara S, Itoh C, Yoshida T, Yamanaka K, Toyoshima S, Katoh J, Kudoh M, Matsushima T, Niki Y, Miyashita N, Funato T, Kaku M, Sato N, Saito Y, Ishii K, Kuwabara M, Hongo T, Negayama K, Kamihira S, Miyazaki Y, Takii M, Ishii M, Nakagawa K, Ono J, Takada T, Murakami N, Taira M, Tamaki I, Matsudou Y, Nakasone I.
    Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
    [Abstract] [Full Text] [Related]

  • 14. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
    Pontani D, Washton H, Bouchillon S, Johnson J.
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
    [Abstract] [Full Text] [Related]

  • 15. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT, Counts C, Lody C, Carter O, Dodson S, Ojha N.
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [Abstract] [Full Text] [Related]

  • 16. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
    Bongaerts GP, Hoogkamp-Korstanje JA.
    Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
    [Abstract] [Full Text] [Related]

  • 17. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
    Davies TA, Kelly LM, Hoellman DB, Ednie LM, Clark CL, Bajaksouzian S, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2000 Mar; 44(3):633-9. PubMed ID: 10681330
    [Abstract] [Full Text] [Related]

  • 18. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA, Tayeb OS.
    Microbios; 1993 Mar; 74(300):147-54. PubMed ID: 8396196
    [Abstract] [Full Text] [Related]

  • 19. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
    Cunha BA, Qadri SM, Ueno Y, Walters EA, Domenico P.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
    [Abstract] [Full Text] [Related]

  • 20. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
    Oh JI, Paek KS, Ahn MJ, Kim MY, Hong CY, Kim IC, Kwak JH.
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1564-8. PubMed ID: 8726042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.